- Home
- SPRO vs MPU Comparison
SPRO vs MPU Comparison
Compare SPRO & MPU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPRO
- MPU
- Stock Information
- Founded
- SPRO 2013
- MPU 1989
- Country
- SPRO United States
- MPU Singapore
- Employees
- SPRO N/A
- MPU N/A
- Industry
- SPRO Biotechnology: Pharmaceutical Preparations
- MPU Transportation Services
- Sector
- SPRO Health Care
- MPU Consumer Discretionary
- Exchange
- SPRO Nasdaq
- MPU Nasdaq
- Market Cap
- SPRO 33.0M
- MPU 35.5M
- IPO Year
- SPRO 2017
- MPU 1998
- Fundamental
- Price
- SPRO $3.02
- MPU $1.05
- Analyst Decision
- SPRO Buy
- MPU
- Analyst Count
- SPRO 4
- MPU 0
- Target Price
- SPRO $5.00
- MPU N/A
- AVG Volume (30 Days)
- SPRO 12.5M
- MPU 311.0K
- Earning Date
- SPRO 08-04-2025
- MPU 08-13-2025
- Dividend Yield
- SPRO N/A
- MPU N/A
- EPS Growth
- SPRO N/A
- MPU N/A
- EPS
- SPRO N/A
- MPU N/A
- Revenue
- SPRO $44,584,000.00
- MPU $36,184,000.00
- Revenue This Year
- SPRO N/A
- MPU N/A
- Revenue Next Year
- SPRO N/A
- MPU N/A
- P/E Ratio
- SPRO N/A
- MPU N/A
- Revenue Growth
- SPRO N/A
- MPU N/A
- 52 Week Low
- SPRO $0.51
- MPU $0.49
- 52 Week High
- SPRO $3.06
- MPU $1.98
- Technical
- Relative Strength Index (RSI)
- SPRO 79.94
- MPU 59.61
- Support Level
- SPRO $2.81
- MPU $0.77
- Resistance Level
- SPRO $3.06
- MPU $0.92
- Average True Range (ATR)
- SPRO 0.24
- MPU 0.07
- MACD
- SPRO -0.00
- MPU 0.00
- Stochastic Oscillator
- SPRO 93.75
- MPU 97.73
About SPRO Spero Therapeutics Inc.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
About MPU Mega Matrix Corp.
Mega Matrix Inc formerly Mega Matrix Inc is a holding company. It operates through its two subsidiaries Mega Metaverse Corp (Mega) and JetFleet Management Corp (JMC). The Company has two business segments which are comprised of : ETH staking business and The leasing of regional aircraft to foreign and domestic regional airlines. The majority of the company's revenue is earned through Leasing business segment. The company operates in USA and Canada, Asia-Pacific, Europe, Middle East and Africa, and Latin America.